Oklo stock tumbles as Financial Times scrutinizes valuation
Eric Venker, President & Immunovant CEO of Roivant Sciences Ltd (NASDAQ:ROIV), sold 851,383 common shares in multiple transactions from October 15 to October 17, 2025, for a total of $14,467,502. The shares were sold at prices ranging from $16.93 to $17.06.
The sales followed the exercise of stock options to acquire a total of 851,383 common shares at a price of $15.85, for a total value of $13,494,420.
Following these transactions, Venker directly owns 1,504,959 shares of Roivant Sciences Ltd.
In other recent news, Roivant Sciences has announced successful results from its Phase 3 VALOR trial for the treatment of dermatomyositis with its once-daily oral medication, brepocitinib. The trial demonstrated significant improvement in patients, achieving a mean Total Improvement Score of 46.5 compared to 31.2 for the placebo group. Following these positive results, Goldman Sachs has increased its price target for Roivant Sciences to $24, maintaining a Buy rating, and H.C. Wainwright has raised its target to $20, also keeping a Buy rating. These developments highlight the potential for Roivant’s pipeline to generate substantial sales in the future.
Both Goldman Sachs and H.C. Wainwright view the trial outcomes as a key step in Roivant’s growth trajectory. The VALOR trial results showed brepocitinib’s effectiveness in improving various disease symptoms, even with a steroid tapering design. Analysts from Goldman Sachs project that Roivant’s pipeline could achieve over $10 billion in peak sales. The trial’s success has been seen as a promising start to a transformative period for the company, aiming to establish a robust multi-product commercial franchise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.